Key facts
- Elephas’s last known valuation is $281.0M (Nov 2025).
- It has raised $167.2M across 4 recorded rounds; the latest was Later Stage VC ($51.2M) in Nov 2023.
- Notable investors include ARCH Venture Partners, Moore Strategic Ventures, Sands Capital, Tao Capital Partners, WARF Ventures — 9 tracked in total.
- Elephas has filed 4 Form Ds with the SEC since 2021, most recently Jan 2024 ($51.2M sold to 10 investors).
- Status: Privately Held (backing).
Leadership
- Carolyn MorganExecutive
- Hinco GiermanChief Scientific Officer
- Premal PatelChief Medical Officer
- Terry BradyChief Financial Officer
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Elephas
Funding rounds
4 roundsAbout Elephas
Operator of a live tumor imaging diagnostics company intended to determine the cancer therapy for each patient. The company's platform harnesses the latest advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, and focuses on human live tumor fragments, enabling clinicians to treat cancer patients and accelerate drug development.
- Sector
- Healthcare
- HQ
- Madison, WI, United States
- Founded
- 2020
- Employees
- 100
- Website
- elephas.com/
- Ownership
- Privately Held (backing)
Elephas doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elephas shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elephas in its N-PORT filings yet. We sweep new filings monthly.